Sugi Predict

Sugi Predict / Compounds / SCHEMBL320646

SCHEMBL320646

SCHEMBL320646

COC[C@H](C)Oc1cc(O)cc(C(=O)OC)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 3/20 0.54
▸ CA1 P00915 3/20 0.54
▸ CA2 P00918 3/20 0.54
▸ CA7 P43166 3/20 0.54
▸ CA9 Q16790 3/20 0.54
▸ CA14 Q9ULX7 3/20 0.54
▸ GCK P35557 14/20 0.44
▸ KDM4E B2RXH2 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ NFKB1 P19838 1/20 0.41
▸ XDH P47989 1/20 0.41
▸ GFER P55789 1/20 0.41
▸ NFKB2 Q00653 1/20 0.41
▸ RELA Q04206 1/20 0.41
▸ FUT7 Q11130 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ RARA P10276 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2088534 1.00 CA12 (0.54) CA12CA1CA2CA7CA9
SCHEMBL1426494 1.00 CA12 (0.54) CA12CA1CA2CA7CA9
SCHEMBL2175603 0.91 GCK (0.47) CA12CA1CA2CA7CA9
SCHEMBL1107633 0.91 GCK (0.50) CA12CA1CA2CA7CA9
SCHEMBL1107705 0.87 GCK (0.48) CA1CA2GCKKDM4EGAA
SCHEMBL1042110 0.87 CA12 (0.56) CA12CA1CA2CA7CA9
SCHEMBL320803 0.87 GCK (0.50) CA12CA1CA2CA7CA9
SCHEMBL12774009 0.87 CA12 (0.56) CA12CA1CA2CA7CA9
SCHEMBL2654383 0.87 GCK (0.50) CA12CA1CA2CA7CA9
SCHEMBL1107701 0.87 GCK (0.56) GCKRARARARBGRM5RARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2048137-A1 Benzamide derivatives and their use as glucokinase activating agents. AstraZeneca AB (SE) 2009-04-15 — — EP claimed
EP-2059522-B1 PHOSPHONATE AND PHOSPHINATE COMPOUNDS AS GLUCOKINASE ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2014-01-08 — — EP disclosed
EP-2197849-B1 N- ( PYRAZOLE- 3 -YL) -BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS MERCK PATENT GMBH (DE) 2013-02-27 — — EP disclosed
EP-2197849-B1 N- ( PYRAZOLE- 3 -YL) -BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS MERCK PATENT GMBH (DE) 2013-02-27 — — EP disclosed
US-8236824-B2 N-(pyrazole-3-yl)-benzamide derivatives as glucokinase activators MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2012-08-07 — — US disclosed
US-8236824-B2 N-(pyrazole-3-yl)-benzamide derivatives as glucokinase activators MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2012-08-07 — — US disclosed
US-8236824-B2 N-(pyrazole-3-yl)-benzamide derivatives as glucokinase activators MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2012-08-07 — — US disclosed
US-8222285-B2 1,3-dihydroxy substituted phenylamide glucokinase activators BRISTOL-MYERS SQUIBB COMPANY (US) 2012-07-17 — — US disclosed
US-8222285-B2 1,3-dihydroxy substituted phenylamide glucokinase activators BRISTOL-MYERS SQUIBB COMPANY (US) 2012-07-17 — — US disclosed
US-8211925-B2 Benzamide glucokinase activators TRANSTECH PHARMA, INC. (US) 2012-07-03 — — US disclosed
US-20080009465-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME BRISTOL-MYERS SQUIBB COMPANY 2008-01-10 — — US disclosed
WO-2007125103-A2 BENZAMIDE GLUCOKINASE ACTIVATORS TRANSTECH PHARMA, INC. (US) 2007-11-08 — — WO disclosed
WO-2007125105-A2 BENZAMIDE GLUCOKINASE ACTIVATORS TRANSTECH PHARMA, INC. (US) 2007-11-08 — — WO disclosed
WO-2007007041-A1 HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES ASTRAZENECA AB (SE) 2007-01-18 — — WO disclosed
WO-2007007042-A1 HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES ASTRAZENECA AB (SE) 2007-01-18 — — WO disclosed
WO-2007007040-A1 2 -HETEROCYCLYLOXYBENZOYL AMINO HETEROCYCLYL COMPOUNDS AS MODULATORS OF GLUCOKINASE FOR THE TREATMENT OF TYPE 2 DIABETES ASTRAZENECA AB (SE) 2007-01-18 — — WO disclosed
WO-2006125958-A1 2-PHENYL SUBSTITUTED IMIDAZOL [4 , 5B] PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS ASTRAZENECA AB (SE) 2006-11-30 — — WO disclosed
WO-2006125958-A1 2-PHENYL SUBSTITUTED IMIDAZOL [4 , 5B] PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS ASTRAZENECA AB (SE) 2006-11-30 — — WO disclosed
EP-1718624-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATING AGENTS AstraZeneca AB (SE) 2006-11-08 — — EP disclosed
WO-2005080359-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINAE ACTIVATING AGENTS ASTRAZENECA AB (SE) 2005-09-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009465-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME GCKR, GCK, PCK1 CA12 2553/4885CA1 2179/4885CA2 846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.